In response to a report of upbeat clinical data from two phase 3 trials, shares of Vertex Pharmaceuticals (NASDAQ: VRTX) rose by 23% as of 11:15 a.m. EDT on Wednesday.Image source: Getty Images.Vertex announced results from its phase 3 EVOLVE and EXPAND studies. Both of these trials were designed to test the efficacy and safety of a drug that combines Vertex's next-generation cystic fibrosis (CF) treatment tezacaftor with its already approved CF drug ivacaftor, which is marketed as Kalydeco. Continue reading